GLPwatch

Oxyntomodulin analog and exendin-4 derivative lower plasma glucose in cattle.

Domest Anim Endocrinol · 2017

Last updated 2026-05-28

In cattle, a modified version of oxyntomodulin called [Gly, Glu]-OXM lowered blood sugar and increased insulin, while a glucagon-based compound called [Gly, Glu]-glucandin also raised insulin but required a higher dose of 3.2 micrograms per kilogram to affect blood sugar. Another compound, [Gly, Glu]-glucagon, increased insulin but did not change blood sugar levels. The effects of [Gly, Glu]-OXM were nearly as strong as a diabetes drug called Ex-4 in lowering blood sugar.

AI summary of the abstract below.

JournalDomest Anim Endocrinol, 2017
Citations3
Relative citation ratio0.12
NIH percentile9
Molecules

Abstract

The present study was undertaken with the aim of examining whether and how exendin-4 (1-3) fragment, ie, Ex-4 (1-3) fragment, contributes to the regulation of glucose. An analog of oxyntomodulin (OXM) ([Gly, Glu]-OXM), a glucagon analog ([Gly, Glu]-glucagon), and two derivatives of Ex-4 (glucandin and [Gly, Glu]-glucandin) were synthesized by substituting with Gly, Glu at the N-terminuses of OXM and glucagon and/or by attaching Ex-4 (30-39) amide at the C-terminus of glucagon. Effects of these peptides on plasma insulin and glucose concentrations were investigated in cattle by conducting 3 in vivo experiments. In all 3 experiments, 0.1% BSA saline was injected as a control. In experiment 1, glucandin (amino acid sequence was glucagon [1-29]-Ex-4 [30-39] amide) and [Gly, Glu]-glucandin were injected at the dose rates of 5 μg/kg BW in 4-mo-old Holstein steers. Results showed that glucoregulatory effects of glucandin were similar to those of glucagon. [Gly, Glu]-glucandin stimulated insulin secretion at 2 to 10 min and lowered glucose concentrations at 15 to 75 min. Experiment 2 was carried out to better understand the glucose-lowering potency of [Gly, Glu]-glucandin, in comparison with Ex-4 and glucagon-like peptide-1 (GLP-1), using 4.5-mo-old Holstein steers. [Gly, Glu]-glucandin was injected at dose rates of 0.3 μg/kg BW, 1.0 μg/kg BW, 3.2 μg/kg BW, and 6.4 μg/kg BW. Ex-4 and GLP-1 were injected at dose rates of 0.3 μg/kg BW. Results showed that the insulinotropic and glucose-lowering effects of [Gly, Glu]-glucandin were not as potent as for Ex-4 and GLP-1, and the minimum effective dose of [Gly, Glu]-glucandin to regulate plasma glucose concentrations was 3.2 μg/kg BW. In experiment 3, [Gly, Glu]-OXM and [Gly, Glu]-glucagon were injected at dose rates of 5 μg/kg BW in 5-mo-old Holstein steers. Both [Gly, Glu]-OXM and [Gly, Glu]-glucagon increased insulin concentration. [Gly, Glu]-OXM potently lowered plasma glucose, but [Gly, Glu]-glucagon did not change it. In summary, our findings clearly demonstrate that Ex-4 (1-3) fragment contributes to the regulation of glucose. [Gly, Glu]-OXM and [Gly, Glu]-glucandin are insulinotropic and glucose-lowering peptides. It was of interest that the substitution of the first 3 amino acids of OXM with Ex-4 (1-3) could reverse the upregulation of glucose by OXM into downregulation of glucose. In lowering glycemia, [Gly, Glu]-OXM seemed almost as effective as Ex-4, and [Gly, Glu]-glucandin was less profound than Ex-4. These findings contributed new insights into the hormonal regulation of glucose in ruminants. The action of [Gly, Glu]-OXM and [Gly, Glu]-glucandin might provide an advantage in glycemic control of insulin resistance in cattle and humans.

Verbatim abstract via PubMed 27888738 ↗